Dharita Roy

“So, Rashi, you have to account for a higher domestic growth. So, that is a high gross margin business and chronic distribution is also increasing. So, that is leading to that kind of margin drop down.”

“I think what Rajesh has told, we specifically launch limited products and individual products try to make it big. So if you see in recent launches, our bonaprasan has become number one, which is our bonalong.”

“Shiddharth, to answer this, I think scientifically, if you see in last few months, there has not been a direct impact on the primary anti-diabetic and cardiac therapy.”